Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat plus darolutamide in metastatic castration-resistant prostate cancer
jRCT2031250584Phase 1Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of valemetostat and darolutamide in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of participants with dose-limiting toxicities and Number of participants experiencing a treatment-emergent adverse event. Started Jan 2026; status: recruiting.
02
Drugs
valemetostatdarolutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031250584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250584.